Research Hot line

UPDATE FROM THE CUTTING EDGE

Jan.-Mar. 2008

The abstracts of the recent research information appearing in Vol.8 No.1-3 of "AIST TODAY" are introduced here, classified by research area. For inquiry about the full article, please contact the author via e-mail.

Life Science & Technology

Isolation of enzyme involving in activation of vitamin D

High-efficient production of hydroxylated vitamin D used for pharmaceutical purposes

It has been known that vitamin D₃ (VD3) is hydroxylated in liver and kidney by cytochrome P450 monooxygenases (CYPs) in animals, resulting in the formation of 1α, 25-dihydroxy VD3 (calcitriol) which modulates calcium metabolism. Calcitriol and its derivatives are used as pharmaceuticals for rickets, osteoporosis and parathyroidosis. About 20 processes are, however, required in chemical synthesis of calcitriol and its yield is very low. Alternate production of calcitriol is carried out by the use of an actinomycete *Pseudonocardia autotrophica* as a converter; the cell efficiently converts VD3 to calcitriol by endogenous CYP. We therefore isolated the CYP involved in the VD3 hydroxylation (VDH) and subsequently cloned the corresponding gene from *P. autotrophica*. Conversion of VD3 to calcitriol was observed using recombinant VDH and its redox partners in an *in vitro* reconstitution assay. We also confirmed that *Rhodococcus* cells expressing VDH and redox partner proteins were capable of the biotransformation of VD3. Mutational engineering of the *vdh* gene and genetic engineering of appropriate host cells will dramatically improve the productivity of


hydroxylated VD3s in the near future.

*This is the result of a joint research with Mercian Corp. (Iwata, Japan).

Tomohiro Tamura

Research Institute of Genome-based Biofactory t-tamura@aist.go.jp

AIST TODAY Vol.8, No.1 p.26 (2008)



Activation of vitamin D by actinomycete and pharmacological effect of hydroxylated vitamin D